Eloxx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ELOX) $1.10 -0.01 (-0.90%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$1.10▼$1.1250-Day Range$1.07▼$4.9152-Week Range$0.95▼$10.90Volume2,584 shsAverage Volume436,871 shsMarket Capitalization$3.46 millionP/E RatioN/ADividend YieldN/APrice Target$55.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Eloxx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside4,900.0% Upside$55.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($7.91) to ($7.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.68 out of 5 stars 3.5 Analyst's Opinion Consensus RatingEloxx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $55.00, Eloxx Pharmaceuticals has a forecasted upside of 4,900.0% from its current price of $1.10.Amount of Analyst CoverageEloxx Pharmaceuticals has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ELOX. Previous Next 0.0 Dividend Strength Dividend YieldEloxx Pharmaceuticals does not currently pay a dividend.Dividend GrowthEloxx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELOX. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 1 people have added Eloxx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders20.20% of the stock of Eloxx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.64% of the stock of Eloxx Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Eloxx Pharmaceuticals are expected to grow in the coming year, from ($7.91) to ($7.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eloxx Pharmaceuticals is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eloxx Pharmaceuticals is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX)Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.Read More ELOX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELOX Stock News HeadlinesNovember 22, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Biomea Fusion (BMEA) and Medtronic (MDT)November 14, 2023 | msn.comHoth stock jumps on positive FDA feedback on drug HT-KITDecember 6, 2023 | Financial Alphas (Ad)Lithium Discovery So BIG You Can't Miss it, Even From SpaceWith the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!November 13, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business UpdateNovember 8, 2023 | morningstar.comEloxx Pharmaceuticals Inc ELOXOctober 9, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of ProteinuriaSeptember 21, 2023 | seekingalpha.comEloxx Pharmaceuticals prices $2M stock offeringSeptember 19, 2023 | markets.businessinsider.comEloxx Pharmaceuticals Announces Registered Direct Offering - Quick FactsDecember 6, 2023 | Financial Alphas (Ad)Lithium Discovery So BIG You Can't Miss it, Even From SpaceWith the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!September 19, 2023 | finance.yahoo.comEloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesSeptember 18, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeSeptember 8, 2023 | msn.comEloxx moves ahead with plans with gene therapy for rare kidney disorderSeptember 7, 2023 | finance.yahoo.comEloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013August 30, 2023 | fool.comEloxx Pharmaceuticals (NASDAQ: ELOX)August 15, 2023 | msn.comEloxx reports all patients in Phase II Alport syndrome trial have improvedAugust 14, 2023 | markets.businessinsider.comEloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business UpdateAugust 14, 2023 | msn.comEloxx Pharma (NASDAQ:ELOX) Rises On Promising Phase 2 Data In Alport SyndromeAugust 14, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeAugust 14, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeJuly 11, 2023 | msn.comEloxx, Airbnb, Tesla, PainReform, Roku: Why These 5 Stocks Are Drawing Investor Attention TodayJuly 11, 2023 | benzinga.comEloxx Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Up 111.3%July 11, 2023 | msn.comOppenheimer Maintains Eloxx Pharmaceuticals (ELOX) Outperform RecommendationJuly 11, 2023 | benzinga.comWhy Eloxx Pharmaceuticals (ELOX) Stock Is Soaring TuesdayJuly 11, 2023 | benzinga.comOppenheimer Maintains Outperform on Eloxx Pharmaceuticals, Raises Price Target to $55July 10, 2023 | finance.yahoo.comEloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic BenefitJune 28, 2023 | finance.yahoo.comEloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02June 21, 2023 | finance.yahoo.comEloxx Pharmaceuticals to Host Investor and Analyst Call on Alport SyndromeSee More Headlines Receive ELOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ELOX CUSIPN/A CIK1035354 Webwww.eloxxpharma.com Phone(781) 577-5300Fax908-864-4440Employees18Year Founded2013Price Target and Rating Average Stock Price Target$55.00 High Stock Price Target$55.00 Low Stock Price Target$55.00 Potential Upside/Downside+4,810.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($9.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,060,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-203.00% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.92) per share Price / Book-0.23Miscellaneous Outstanding Shares3,143,000Free Float2,508,000Market Cap$3.52 million OptionableNot Optionable Beta2.65 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Sumit Aggarwal M.B.A. (Age 50)President, CEO & Director Comp: $839.67kMr. Daniel E. Geffken M.B.A. (Age 66)Interim CFO, Principal Financial Officer & Principal Accounting Officer Comp: $63.96kMs. Barbara RyanInvestor Relations OfficerDr. Ali Hariri M.D.Chief Medical OfficerKey CompetitorsTradeUP AcquisitionNASDAQ:UPTDAxcella HealthNASDAQ:AXLABrickell BiotechNASDAQ:BBIWindtree TherapeuticsNASDAQ:WINTTitan PharmaceuticalsNASDAQ:TTNPView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 275,000 shares on 11/15/2023Ownership: 10.000%View All Institutional Transactions ELOX Stock Analysis - Frequently Asked Questions Should I buy or sell Eloxx Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eloxx Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ELOX shares. View ELOX analyst ratings or view top-rated stocks. What is Eloxx Pharmaceuticals' stock price target for 2024? 1 Wall Street research analysts have issued 1 year price objectives for Eloxx Pharmaceuticals' stock. Their ELOX share price targets range from $55.00 to $55.00. On average, they expect the company's share price to reach $55.00 in the next year. This suggests a possible upside of 4,900.0% from the stock's current price. View analysts price targets for ELOX or view top-rated stocks among Wall Street analysts. How have ELOX shares performed in 2023? Eloxx Pharmaceuticals' stock was trading at $1.82 at the beginning of 2023. Since then, ELOX stock has decreased by 39.6% and is now trading at $1.10. View the best growth stocks for 2023 here. How were Eloxx Pharmaceuticals' earnings last quarter? Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) posted its earnings results on Monday, November, 13th. The company reported ($1.31) earnings per share for the quarter, topping the consensus estimate of ($1.97) by $0.66. What is Greg Williams' approval rating as Eloxx Pharmaceuticals' CEO? 1 employees have rated Eloxx Pharmaceuticals Chief Executive Officer Greg Williams on Glassdoor.com. Greg Williams has an approval rating of 49% among the company's employees. This puts Greg Williams in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Eloxx Pharmaceuticals to a friend. Who are Eloxx Pharmaceuticals' major shareholders? Eloxx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (10.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel E Geffken, Pontifax Management 4 GP (20 and Rajesh B Parekh. View institutional ownership trends. How do I buy shares of Eloxx Pharmaceuticals? Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ELOX) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.